Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Entresto Risk Sharing Could Equate To 8.6% Discount, ICER Says; Is Express Scripts Interested?

This article was originally published in The Pink Sheet Daily

Executive Summary

Cost effectiveness report on Novartis’ new heart failure drug includes a hypothetical risk-sharing payment model using hospitalization or death as patient endpoints; Express Scripts exec notes outcomes-based contracts have been problematic but hints at potential for Entresto.

Advertisement

Related Content

Novartis' Entresto: Slow Uptake Expected Following Fast FDA Approval

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS078917

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel